search
Back to results

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

Primary Purpose

Acute Promyelocytic Leukemia

Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
ATRA
Idarubicina
Mitoxantrone
ARA-C
Sponsored by
PETHEMA Foundation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Promyelocytic Leukemia focused on measuring Acute Promyelocytic Leukemia

Eligibility Criteria

undefined - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≤ 75 years.
  • ECOG ≤ 3.
  • Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical morphology but with PML-RARα reordering also must be including.
  • Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RARα reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody anti-PML (positive PGM3). Obvious, it will be had the result of these tests once initiated the treatment on the basis of a suspicion diagnoses morphologic

Exclusion Criteria:

  • Age >75 years (the treatment with this protocol can be considered individually)
  • Absence of PML-Rare reordering.
  • To have received previously some type of treatment for LPA, including chemotherapy or retinoides. The previous treatment with corticoids, hidroxiurea or leucoaféresis is not reason for exclusion.
  • To have received chemotherapy or x-ray for the treatment of a disease vitiates previous.
  • Associate Neoplasia.
  • Serious psychiatric Disease.
  • Seropositividad for VIH.
  • Contraindication to receive intensive chemotherapy, specially antraciclinas.
  • Sérica Creatinina ≥ 2,5 mg/dL (≥ 250 μmol/l).
  • Bilirrubina, fosfatasa alkaline, or GOT > 3 times the normal limit
  • Test of positive pregnancy.

Sites / Locations

  • PALG
  • Hospital General
  • Hospital general
  • Hospital germans Trias i Pujol
  • Hospital Clinic
  • Hospital de Sant Pau
  • Institut Català d'Oncologái
  • Basurtuko Ospitalea
  • Hospital general
  • Hospital de Fuenlabrada
  • Hospital "Dr. Trueta"
  • Hospital de Jerez de la Frontera
  • Hospital Juan Canalejo
  • Hospital Insular de las Palmas
  • Complejo Hospitalario León
  • Complexo Hospitalario Xeral-Calde
  • Hospital 12 de Octubre
  • Hospital Clínico San Carlos
  • Hospital Puerta de Hierro
  • Hospital Reina Sofia
  • Hospital San Pedro de Alcántara
  • Hospital Severo Ochoa
  • Hospital Sta. Maria del Rosell
  • H. Carlos Haya
  • H. Universitario Virgen de la Victoria
  • Hospital Central de Asturias
  • Hospital Dr Negrín
  • Hospital de Navarra
  • Hospital de Montecelo
  • Hospital Clínico Universitario
  • Hospital de Cruces
  • Hospital de Santiago de Compostela
  • H.U. Virgen del Rocio
  • Hospital Joan XXIII
  • Hospital Dr. Peset
  • Hospital general
  • Hospital La Fe
  • Hospital Clínico de Valladolid
  • Hospital Txagorritxu
  • Hospital Virgen de la Concha
  • Hospital Clínico Universitario Lozano Blesa
  • Hospital Maciel

Outcomes

Primary Outcome Measures

To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL.
To evaluate the impact of mitoxantrone reduction on the event-free, disease-free, and overall survival.
To evaluate the impact of the addition of ara-C to idarubicin courses of consolidation for high-risk patients on the event-free, disease-free, and overall survival
To evaluate the toxicity of the induction, consolidation, and maintenance chemotherapy in the whole series and in each treatment group in patients with APL.

Secondary Outcome Measures

To compare all outcomes with those achieved with the PETHEMA LPA99 protocol.

Full Information

First Posted
December 5, 2006
Last Updated
October 27, 2014
Sponsor
PETHEMA Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00408278
Brief Title
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Official Title
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005): Remission Induction With ATRA + Idarubicin. Risk-adapted Consolidation With ATRA and Anthracycline-based Chemotherapy (Idarubicin/Mitoxantrone) With Addition of Ara-C for High-risk Patients. Maintenance Therapy With ATRA + Low Dose Chemotherapy (Methotrexate + Mercaptopurine).
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
July 2005 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PETHEMA Foundation

4. Oversight

5. Study Description

Brief Summary
Primary objectives To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL. To evaluate the impact of mitoxantrone reduction on the event-free, disease-free, and overall survival, as well as on the duration of remission and cumulative incidence of relapse in low- and intermediate-risk patients with APL. To evaluate the impact of the addition of ara-C to idarubicin courses of consolidation for high-risk patients (administered as in the original GIMEMA protocols) on the event-free, disease-free, and overall survival, as well as on the duration of remission and cumulative incidence of relapse. To evaluate the toxicity of the induction, consolidation, and maintenance chemotherapy in the whole series and in each treatment group in patients with APL. Secondary objectives • To compare all outcomes with those achieved with the PETHEMA LPA99 protocol.
Detailed Description
Treatment of induction with the simultaneous administration of ATRA (45 mg/m2 day until the RC) and idarubicine (12 mg/m2 days 2, 4, 6 and 8), 3 monthly cycles of consolidation with ATRA (45 mg/m2 days 1-15) and idarubicine (5 mg/m2 days 1-4) in the cycle #1, mitoxantrone (10 mg/m2 days 1-3) in the cycle #2 and idarubicine (12 mg/m2 day 1) in the cycle #3. The consolidation was reinforced for the group of patients with intermediate risk by means of an increase of the idarubicine to 7 mg in the cycle #1 and to 2 days in the cycle #3. In the patients of high risk, the consolidation was reinforced with the addition of altar-c in the cycles #1 and #3. For the maintenance treatment, one will administer to intermittent ATRA (15 days every 3 months) and chemotherapy low doses with methotrexate and 6-mercaptopurina during two years

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Promyelocytic Leukemia
Keywords
Acute Promyelocytic Leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
ATRA
Intervention Description
45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
Intervention Type
Drug
Intervention Name(s)
Idarubicina
Intervention Description
Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
Intervention Type
Drug
Intervention Name(s)
Mitoxantrone
Intervention Description
Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
Intervention Type
Drug
Intervention Name(s)
ARA-C
Intervention Description
In high risk patients, consolidation with ara-C in cycles 1 and 3.
Primary Outcome Measure Information:
Title
To evaluate the efficacy and toxicity of a risk-adapted protocol that use idarubicin for induction and consolidation therapy in patients with APL.
Time Frame
1 year
Title
To evaluate the impact of mitoxantrone reduction on the event-free, disease-free, and overall survival.
Time Frame
1 year
Title
To evaluate the impact of the addition of ara-C to idarubicin courses of consolidation for high-risk patients on the event-free, disease-free, and overall survival
Time Frame
1 year
Title
To evaluate the toxicity of the induction, consolidation, and maintenance chemotherapy in the whole series and in each treatment group in patients with APL.
Time Frame
1 year
Secondary Outcome Measure Information:
Title
To compare all outcomes with those achieved with the PETHEMA LPA99 protocol.
Time Frame
2 years

10. Eligibility

Sex
All
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≤ 75 years. ECOG ≤ 3. Morphologic Diagnosis of LPA (FAB M3 or variant M3). Those cases without typical morphology but with PML-RARα reordering also must be including. Genetic Diagnosis: t (15; 17) demonstrated by cariotipo conventional, FISH, PML-RARα reordering detected by RT-PCR or a pattern microspeckled demonstrated with antibody anti-PML (positive PGM3). Obvious, it will be had the result of these tests once initiated the treatment on the basis of a suspicion diagnoses morphologic Exclusion Criteria: Age >75 years (the treatment with this protocol can be considered individually) Absence of PML-Rare reordering. To have received previously some type of treatment for LPA, including chemotherapy or retinoides. The previous treatment with corticoids, hidroxiurea or leucoaféresis is not reason for exclusion. To have received chemotherapy or x-ray for the treatment of a disease vitiates previous. Associate Neoplasia. Serious psychiatric Disease. Seropositividad for VIH. Contraindication to receive intensive chemotherapy, specially antraciclinas. Sérica Creatinina ≥ 2,5 mg/dL (≥ 250 μmol/l). Bilirrubina, fosfatasa alkaline, or GOT > 3 times the normal limit Test of positive pregnancy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
San Miguel Miguel Angel, Dr
Organizational Affiliation
HOSPITAL LA FE VALENCIA
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Vellenga Edo, Dr
Organizational Affiliation
Stichting Hemato-Oncologie voor Volwassenen Nederland
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Lowenberg Bob, Dr
Organizational Affiliation
Stichting Hemato-Oncologie voor Volwassenen Nederland
Official's Role
Study Director
Facility Information:
Facility Name
PALG
City
Lodz
Country
Poland
Facility Name
Hospital General
City
Albacete
Country
Spain
Facility Name
Hospital general
City
Alicante
Country
Spain
Facility Name
Hospital germans Trias i Pujol
City
Badalona
Country
Spain
Facility Name
Hospital Clinic
City
Barcelona
Country
Spain
Facility Name
Hospital de Sant Pau
City
Barcelona
Country
Spain
Facility Name
Institut Català d'Oncologái
City
Barcelona
Country
Spain
Facility Name
Basurtuko Ospitalea
City
Bilbao
Country
Spain
Facility Name
Hospital general
City
Castellon
Country
Spain
Facility Name
Hospital de Fuenlabrada
City
Fuenlabrada
Country
Spain
Facility Name
Hospital "Dr. Trueta"
City
Gerona
Country
Spain
Facility Name
Hospital de Jerez de la Frontera
City
Jerez de la Frontera
Country
Spain
Facility Name
Hospital Juan Canalejo
City
La Coruña
Country
Spain
Facility Name
Hospital Insular de las Palmas
City
Las Palmas de Gran Canaria
Country
Spain
Facility Name
Complejo Hospitalario León
City
Leon
Country
Spain
Facility Name
Complexo Hospitalario Xeral-Calde
City
Lugo
Country
Spain
Facility Name
Hospital 12 de Octubre
City
Madrid
Country
Spain
Facility Name
Hospital Clínico San Carlos
City
Madrid
Country
Spain
Facility Name
Hospital Puerta de Hierro
City
Madrid
Country
Spain
Facility Name
Hospital Reina Sofia
City
Madrid
Country
Spain
Facility Name
Hospital San Pedro de Alcántara
City
Madrid
Country
Spain
Facility Name
Hospital Severo Ochoa
City
Madrid
Country
Spain
Facility Name
Hospital Sta. Maria del Rosell
City
Murcia
Country
Spain
Facility Name
H. Carlos Haya
City
Málaga
Country
Spain
Facility Name
H. Universitario Virgen de la Victoria
City
Málaga
Country
Spain
Facility Name
Hospital Central de Asturias
City
Oviedo
Country
Spain
Facility Name
Hospital Dr Negrín
City
Palma de Gran Canaria
Country
Spain
Facility Name
Hospital de Navarra
City
Pamplona
Country
Spain
Facility Name
Hospital de Montecelo
City
Pontevedra
Country
Spain
Facility Name
Hospital Clínico Universitario
City
Salamanca
Country
Spain
Facility Name
Hospital de Cruces
City
Santander
Country
Spain
Facility Name
Hospital de Santiago de Compostela
City
Santiago de Compostela
Country
Spain
Facility Name
H.U. Virgen del Rocio
City
Sevilla
Country
Spain
Facility Name
Hospital Joan XXIII
City
Tarragona
Country
Spain
Facility Name
Hospital Dr. Peset
City
Valencia
Country
Spain
Facility Name
Hospital general
City
Valencia
Country
Spain
Facility Name
Hospital La Fe
City
Valencia
Country
Spain
Facility Name
Hospital Clínico de Valladolid
City
Valladolid
Country
Spain
Facility Name
Hospital Txagorritxu
City
Vitoria
Country
Spain
Facility Name
Hospital Virgen de la Concha
City
Zamora
Country
Spain
Facility Name
Hospital Clínico Universitario Lozano Blesa
City
Zaragoza
Country
Spain
Facility Name
Hospital Maciel
City
Montevideo
Country
Uruguay

12. IPD Sharing Statement

Citations:
PubMed Identifier
11806975
Citation
Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood. 2002 Feb 1;99(3):759-67. doi: 10.1182/blood.v99.3.759.
Results Reference
background
PubMed Identifier
12886231
Citation
Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate. Leukemia. 2003 Aug;17(8):1454-63. doi: 10.1038/sj.leu.2403031.
Results Reference
background
PubMed Identifier
12935961
Citation
Sanz MA, Martin G, Lo Coco F. Choice of chemotherapy in induction, consolidation and maintenance in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003 Sep;16(3):433-51. doi: 10.1016/s1521-6926(03)00040-9.
Results Reference
background
PubMed Identifier
9440726
Citation
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol. 1998 Jan;16(1):78-85. doi: 10.1200/JCO.1998.16.1.78.
Results Reference
background
PubMed Identifier
10361110
Citation
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood. 1999 Jun 15;93(12):4131-43.
Results Reference
background
PubMed Identifier
10438706
Citation
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200.
Results Reference
background
PubMed Identifier
10942230
Citation
Lengfelder E, Reichert A, Schoch C, Haase D, Haferlach T, Loffler H, Staib P, Heyll A, Seifarth W, Saussele S, Fonatsch C, Gassmann W, Ludwig WD, Hochhaus A, Beelen D, Aul C, Sauerland MC, Heinecke A, Hehlmann R, Wormann B, Hiddemann W, Buchner T. Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia. 2000 Aug;14(8):1362-70. doi: 10.1038/sj.leu.2401843.
Results Reference
background
PubMed Identifier
10942364
Citation
Sanz MA, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, Diaz-Mediavilla J, Fioritoni G, Gonzalez JD, Liso V, Esteve J, Ferrara F, Bolufer P, Bernasconi C, Gonzalez M, Rodeghiero F, Colomer D, Petti MC, Ribera JM, Mandelli F. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000 Aug 15;96(4):1247-53.
Results Reference
background
PubMed Identifier
14576047
Citation
Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, Colomer D, Amutio E, Capote FJ, Milone GA, De La Serna J, Roman J, Barragan E, Bergua J, Escoda L, Parody R, Negri S, Calasanz MJ, Bolufer P; Programa de Estudio y Traitmiento de las Hemopatias Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood. 2004 Feb 15;103(4):1237-43. doi: 10.1182/blood-2003-07-2462. Epub 2003 Oct 23.
Results Reference
background
PubMed Identifier
9389704
Citation
Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood. 1997 Dec 15;90(12):4876-85.
Results Reference
background
PubMed Identifier
10602411
Citation
van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, Diaz MG, Malec M, Langerak AW, San Miguel JF, Biondi A. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999 Dec;13(12):1901-28. doi: 10.1038/sj.leu.2401592.
Results Reference
background
PubMed Identifier
9354674
Citation
Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Pasqualucci L, Biondi A, Riganelli D, Orleth A, Liso A, Martelli MF, Pelicci PG, Pileri S. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood. 1997 Nov 15;90(10):4046-53.
Results Reference
background
PubMed Identifier
15278297
Citation
Gomis F, Sanz J, Sempere A, Plume G, Senent ML, Perez ML, Cervera J, Moscardo F, Bolufer P, Barragan E, Martin G, Sanz MA. Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia. Ann Hematol. 2004 Nov;83(11):687-90. doi: 10.1007/s00277-004-0902-7. Epub 2004 Jul 24.
Results Reference
background
PubMed Identifier
28584252
Citation
Martinez-Cuadron D, Montesinos P, Vellenga E, Bernal T, Salamero O, Holowiecka A, Brunet S, Gil C, Benavente C, Ribera JM, Perez-Encinas M, De la Serna J, Esteve J, Rubio V, Gonzalez-Campos J, Escoda L, Amutio ME, Arnan M, Arias J, Negri S, Lowenberg B, Sanz MA. Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia. 2018 Jan;32(1):21-29. doi: 10.1038/leu.2017.178. Epub 2017 Jun 6.
Results Reference
derived
PubMed Identifier
25975975
Citation
Sanz MA, Montesinos P, Kim HT, Ruiz-Arguelles GJ, Undurraga MS, Uriarte MR, Martinez L, Jacomo RH, Gutierrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, Gonzalez-Huerta AJ, Fernandez P, De la Serna J, Brunet S, De Lisa E, Gonzalez-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Lowenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies. Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15.
Results Reference
derived
PubMed Identifier
21148082
Citation
Montesinos P, Rayon C, Vellenga E, Brunet S, Gonzalez J, Gonzalez M, Holowiecka A, Esteve J, Bergua J, Gonzalez JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Perez I, Perez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.
Results Reference
derived
PubMed Identifier
20393132
Citation
Sanz MA, Montesinos P, Rayon C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, Gonzalez J, Diaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, Gonzalez JD, Lowenberg B; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14.
Results Reference
derived
Links:
URL
http://www.aehh.org
Description
Spanish association of Haematology
URL
http://www.hovon.nl
Description
Hovon Data Center

Learn more about this trial

Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)

We'll reach out to this number within 24 hrs